

The Neo-ACT trial


Newsletter no. 3, September 2023

Jana de Boniface, Cecilia Ringborg, Renske Altena, Yvonne Wengström and Marie Westman



Inclusion is up and running!

Neo-ACT has randomized **36** patients at the open sites of Karolinska (21), St Görän (8), Sahlgrenska (4), Helsinki (2) and Sundsvall (1). Skaraborg, SÖS and Västerås have recently opened and are eagerly awaiting their first patients, while Umeå and Turku will soon follow.



International expansion

We are busy expanding the trial to further international sites via different networks, e.g., EUBREAST (European Breast Cancer Research Association of Surgical Trialists). English-speaking and German-speaking will be the first in line to join us, followed by further countries and languages in due course.


Exciting publication

The Journal of Clinical Oncology recently published the results of the LEANer study by Sanft et al, corroborating the hypothesis of exercise – here combined with a dietary intervention – improving pCR rates. In a randomized trial including 173 women with breast cancer, the secondary outcome pCR was 53% in those assigned to exercise and diet, as compared with 28% in those receiving usual care. A real boost for the Neo-ACT trial and a thumbs-up for our hypothesis!



Neo-ACT Teams meeting

Invites to a Teams meeting has been sent out. There are two options, either 19 Sep 16.00–16.40 or 22 Sep 12.15–12.55. Karolinska staff (Agneta and Karin) will share their experiences, and there will be updates on current status and an opportunity to ask questions.



Homepage

For any purposes and needs, please visit our trial homepage.

<https://ki.se/en/mmk/the-neo-act-trial>

Contact:

Trial management

marie.westman@cytel.com

Queries:

neoact@mmk.ki.se

Kind regards,

The Neo-ACT Team

